Buprenorphine and Amiodarone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Amiodarone
Buprenorphine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Taking amiodarone (a heart rhythm medicine) together with buprenorphine (used for pain or opioid treatment) can cause two things to watch for. First, amiodarone slows down the enzyme that breaks buprenorphine down, so more buprenorphine can build up in your body. That can lead to stronger opioid effects like heavy drowsiness or slowed breathing. Second, both drugs can affect your heart's rhythm, and together they may raise the chance of a rhythm change called QT prolongation.
The good news: your care team can manage this safely by checking your heart with EKGs, watching how you feel, and fine-tuning your buprenorphine dose. Don't stop either medicine on your own. Just talk with your pharmacist or doctor.
Effect: Amiodarone inhibits CYP3A4-mediated metabolism of buprenorphine, increasing buprenorphine exposure and the risk of opioid adverse effects (sedation, respiratory depression). Both agents independently prolong the QT interval, giving additive cardiac conduction risk. Neither drug is a prodrug; the direction is increased buprenorphine effect.
- Severity: Major; evidence: probable; onset: unspecified.
- Monitor: ECG/QTc, electrolytes, sedation and respiratory status.
- Management: Consider reducing buprenorphine dose until stable effects achieved. On amiodarone discontinuation, anticipate reduced exposure and possible withdrawal, adjust dose upward. For long-acting subQ formulations, monitor for over-medication and use a titratable formulation if precise adjustment is needed.
What happens
An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because plasma concentrations of buprenorphine rise when the drug is taken alongside a CYP3A4 inhibitor, extended opioid effects such as respiratory depression can result. There is also a heightened likelihood of QT prolongation when agents that influence cardiac conduction are given together. Should the two be used concurrently, watch the patient carefully for the emergence of a prolonged QT interval. It may be advisable to lower the buprenorphine dose until drug effects have stabilized, while checking often for sedation and respiratory depression. If a CYP3A4 inhibitor is stopped in a patient on buprenorphine, consider raising the buprenorphine dose until stable drug effects are reached, and observe for indications of opioid withdrawal2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is gone, move the patient back to a buprenorphine formulation that allows finer dose titration. For patients switched from transmucosal buprenorphine given with CYP3A4 inhibitors, verify that the plasma buprenorphine level delivered by subQ buprenorphine remains sufficient. For patients already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, monitor for indications of over-medication. If evidence of buprenorphine toxicity or overdose appears but the accompanying medication cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses do not allow the target dose to be met, halt treatment and manage the patient with a buprenorphine formulation that supports more precise dose adjustments 1.
Why it happens (mechanism)
Additive QT interval prolongation; inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
This combination can be used safely with the right oversight. Your care team will typically:
- Keep you on both medicines as prescribed unless they tell you otherwise.
- Check your heart rhythm with an EKG and monitor for excessive drowsiness or slowed breathing.
- Possibly adjust your buprenorphine dose, which may need to be individualized until you have steady, stable effects.
- Re-check your dose if amiodarone is later stopped, since buprenorphine may drop and cause withdrawal.
Call your prescriber or pharmacist right away if you notice unusual sleepiness, confusion, very slow or shallow breathing, fainting, or a pounding or irregular heartbeat.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) In a trial involving healthy volunteers (N=12), giving oral buprenorphine together with voriconazole produced a significant rise in the mean AUC(0 to 18 hours) of buprenorphine by 4.3-fold (from 0.43 to 2.1 nanograms (ng) x hr/mL), an increase in Cmax by 3.9-fold (from 0.057 to 0.22 ng/mL), a longer half-life (from 9.1 to 14.5 hours), and greater urinary clearance (from 0.31 to 0.73 L/hr). Voriconazole likewise significantly raised exposure to the active metabolite norbuprenorphine, with AUC(0 to 18 hours) increasing by nearly 4-fold and Cmax by 3.3-fold, while reducing renal clearance (from 7.2 to 2.9 L/hr). Participants reported mild dizziness and nausea in both phases. Subjects were given either placebo or voriconazole 400 mg twice daily on day 1, then 200 mg twice daily on days 2 to 5, after which there was a 4-week washout period before switching to the alternate regimen. On the fifth day, every subject received a single dose of buprenorphine 0.2 mg orally or 3.6 mg during the placebo phase 3.
b) The impact of concurrent CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Amiodarone together?
Amiodarone raises buprenorphine levels and adds to QT prolongation risk, so watch for excessive sedation, slow breathing, and heart rhythm changes. Keep taking both as prescribed and let your care team manage dosing and heart monitoring. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Amiodarone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Amiodarone interaction managed?
This combination can be used safely with the right oversight. Your care team will typically: Keep you on both medicines as prescribed unless they tell you otherwise. Check your heart rhythm with an EKG and monitor for excessive drowsiness or slowed breathing. Possibly adjust your buprenorphine dose, which may need to be individualized until you have steady, stable effects. Re-check your dose if am… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Buprenorphine or Amiodarone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
- Fihlman M, Hemmila T, Hagelberg NM, et al: Voriconazole greatly increases the exposure to oral buprenorphine. Eur J Clin Pharmacol 2018; 74(12):1615-1622. PubMed
Keep reading about Amiodarone
Keep reading about Buprenorphine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist